OVID Ovid Therapeutics Inc
Price (delayed)
$0.34
Market cap
$24.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.37
Enterprise value
$10.69M
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company believes these
Highlights
Ovid Therapeutics's debt has shrunk by 68% YoY and by 8% QoQ
The EPS is up by 49% YoY and by 20% QoQ
OVID's revenue is up by 44% year-on-year but it is down by 10% since the previous quarter
The gross profit has grown by 44% YoY but it has contracted by 10% from the previous quarter
OVID's quick ratio is down by 44% YoY and by 6% QoQ
OVID's equity is down by 22% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of OVID
Market
Valuations
Earnings
Shares outstanding
71.08M
Market cap
$24.17M
Enterprise value
$10.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.35
Price to sales (P/S)
42.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.88
Revenue
$566,000
Gross profit
$566,000
Operating income
-$61.89M
Net income
-$26.43M
EBIT
-$26.43M
EBITDA
-$24.72M
Free cash flow
-$56.03M
Per share
Balance sheet
Liquidity
EPS
-$0.37
EPS diluted
-$0.37
Free cash flow per share
-$0.79
Book value per share
$0.96
Revenue per share
$0.01
TBVPS
$1.3
Total assets
$92.17M
Total liabilities
$23.94M
Debt
$14.76M
Equity
$68.23M
Working capital
$45.42M
Debt to equity
0.22
Current ratio
5.32
Quick ratio
5.23
Net debt/EBITDA
0.55
Margins
Efficiency
Dividend
EBITDA margin
-4,368%
Gross margin
100%
Net margin
-4,670.1%
Operating margin
-10,933.7%
Return on assets
-23.8%
Return on equity
-33.9%
Return on invested capital
-27.6%
Return on capital employed
-32.4%
Return on sales
-4,670.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OVID stock price
How has the Ovid Therapeutics stock price performed over time
Intraday
9.78%
1 week
-16.46%
1 month
-35.85%
1 year
-88.85%
YTD
-63.59%
QTD
9.01%
Financial performance
How have Ovid Therapeutics's revenue and profit performed over time
Revenue
$566,000
Gross profit
$566,000
Operating income
-$61.89M
Net income
-$26.43M
Gross margin
100%
Net margin
-4,670.1%
Ovid Therapeutics's net margin has surged by 65% YoY and by 9% QoQ
The net income has grown by 49% YoY and by 19% from the previous quarter
OVID's revenue is up by 44% year-on-year but it is down by 10% since the previous quarter
The gross profit has grown by 44% YoY but it has contracted by 10% from the previous quarter
Growth
What is Ovid Therapeutics's growth rate over time
Valuation
What is Ovid Therapeutics stock price valuation
P/E
N/A
P/B
0.35
P/S
42.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.88
The EPS is up by 49% YoY and by 20% QoQ
OVID's price to book (P/B) is 87% less than its 5-year quarterly average of 2.4 and 77% less than its last 4 quarters average of 1.4
OVID's equity is down by 22% YoY and by 11% from the previous quarter
OVID's price to sales (P/S) is 87% less than its 5-year quarterly average of 301.9 and 81% less than its last 4 quarters average of 200.1
OVID's revenue is up by 44% year-on-year but it is down by 10% since the previous quarter
Efficiency
How efficient is Ovid Therapeutics business performance
The ROS has soared by 65% YoY and by 9% QoQ
OVID's ROIC is up by 50% YoY
The return on assets has increased by 38% year-on-year and by 9% since the previous quarter
Ovid Therapeutics's ROE has increased by 32% YoY and by 14% from the previous quarter
Dividends
What is OVID's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OVID.
Financial health
How did Ovid Therapeutics financials performed over time
The total liabilities has plunged by 57% YoY and by 9% from the previous quarter
The company's current ratio fell by 44% YoY and by 6% QoQ
Ovid Therapeutics's debt is 78% lower than its equity
Ovid Therapeutics's debt has shrunk by 68% YoY and by 8% QoQ
Ovid Therapeutics's debt to equity has plunged by 58% YoY but it has increased by 4.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.